TL
VNDA icon

TrueWealth LLC’s Vanda Pharmaceuticals VNDA Stock Holding History

TrueWealth LLC’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-230
Closed -$4K – 769
2019
Q1 		$4K Hold
230
– – ﹤0.01% 613
2018
Q4 		$6K Sell
230
-61
-21% -$1.43K ﹤0.01% 530
2018
Q3 		$7K Sell
291
-91
-24% -$1.86K ﹤0.01% 560
2018
Q2 		$7K Buy
+382
New +$6.39K ﹤0.01% 563

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

TrueWealth LLC's VNDA Position: Q2 2019 in Review

TrueWealth LLC sold out of Vanda Pharmaceuticals (VNDA) in Q2 2019, closing a stake of 230 shares — an estimated $4K sold.

TrueWealth LLC first reported a position in VNDA in Q2 2018 and held it in 4 quarters. The position peaked at $7K in Q3 2018. 164 funds tracked by Wall St. Rank hold VNDA as of Q2 2019.

  • TrueWealth LLC reported no remaining Vanda Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • TrueWealth LLC sold 230 Vanda Pharmaceuticals shares in Q2 2019, an estimated $4K.
  • TrueWealth LLC first reported a position in Vanda Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • TrueWealth LLC's Vanda Pharmaceuticals position peaked at $7K in Q3 2018.
  • 164 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2019.

Based on TrueWealth LLC's 13F filing for Q2 2019, filed 10 Jul 2019.